Family Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Family Management’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,424	Closed	-$14K	–	81
2018 Q2	$14K	Hold	10,424	–	–	0.01%	76
2018 Q1	$15K	Hold	10,424	–	–	0.01%	64
2017 Q4	$23K	Sell	10,424 -47,000	-82%	-$119K	0.02%	58
2017 Q3	$195K	Buy	57,424 +10,000	+21%	+$33.6K	0.13%	59
2017 Q2	$168K	Buy	47,424 +6,416	+16%	+$21.1K	0.12%	60
2017 Q1	$139K	Buy	41,008 +29,000	+242%	+$113K	0.1%	59
2016 Q4	$55K	Buy	+12,008	New	+$49.5K	0.04%	66

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Family Management's AST Position: Q3 2018 in Review

Family Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2018, closing a stake of 10,424 shares — an estimated $14K sold.

Family Management first reported a position in AST in Q4 2016 and held it in 7 quarters. The position peaked at $195K in Q3 2017. 54 funds tracked by Wall St. Rank hold AST as of Q3 2018.

Family Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2018 after selling out during the quarter.
Family Management sold 10,424 Asterias Biotherapeutics Inc. Series A shares in Q3 2018, an estimated $14K.
Family Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2016 and held it in 7 quarters.
Family Management's Asterias Biotherapeutics Inc. Series A position peaked at $195K in Q3 2017.
54 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2018.

Based on Family Management's 13F filing for Q3 2018, filed 13 Nov 2018.